Here to discuss staying ahead of progression in patients with relapsing multiple sclerosis (RMS) is Dr. Timothy William West. Dr. West walks us through pathophysiological changes in progressing RMS patients, a patient case demonstrating why patients may experience increasing disability, and key data on MAYZENT®(siponimod), the first and only oral disease-modifying therapy studied and proven to delay disability progression in a more progressed RMS patient population.
MAYZENT was evaluated in EXPAND—the largest Phase III study of secondary progressive MS (SPMS) patients to date (N=1651), which included a broad range of patients with moderate-to-advanced disability. Dr. West discusses clinical data from EXPAND including data of up to 5 years from a preplanned interim analysis of the EXPAND open-label extension study.